A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Asciminib (Primary) ; Imatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Oct 2018 Planned End Date changed from 24 Aug 2021 to 11 Oct 2021.
- 29 Oct 2018 Planned primary completion date changed from 16 Sep 2020 to 3 Nov 2020.
- 29 Oct 2018 Status changed from not yet recruiting to recruiting.